ADHD Therapeutics Market Revenue Predicted To Go Up

By Christie Abagon , Oct 26, 2016 06:31 PM EDT

ADHD or Attention deficit hyperactivity disorder is a psychiatric disorder which is characterized by problems paying attention, restlessness or difficulty in controlling behavior which is not age appropriate. The study conducted by Persistence Market Research shows an analysis of the factors and trends which impact the market performance of global Ready-To-Use Therapeutic Food for an eight-year period (2016 - 2024).

A study conducted by Persistence Market Research shows an analysis of the factors and trends which impact the market performance of global ready-to-use therapeutic food for an eight-year period (2016 - 2024).

The report considered the revenue from sales of branded, generic, and off-labeled drugs used for the treatment of various CNS (central nervous system) disorders including bipolar disorders, depression, epilepsy, Parkinson's Disease, Alzheimer's Disease, Huntington's disease (HD), multiple sclerosis (MS), schizophrenia, attention-deficit hyperactivity disorder (ADHD), migraine, and anxiety to calculate the market size.

These are some of the key players in the Therapeutic Food Market :

  1.  Concordia International Corp.,
  2.  Eli Lilly and Company,
  3.  Highland Therapeutics Inc.,
  4.  Janssen Global Services LLC,
  5.  NEOS Therapeutics Inc.,
  6.  Novartis AG,
  7.  Noven Pharmaceuticals Inc.,
  8.  Pfizer Inc.,
  9.  Shire,
  10.  Teva Pharmaceutical

The audience intended for this study are the following :

  1.  ADHD drug manufacturers
  2.  ADHD drug suppliers
  3.  Research and Development (R&D) Companies
  4.  Government Research Laboratories
  5.  Independent Research Laboratories
  6.  Government and Independent Regulatory Authorities
  7.  Market Research and Consulting Service Providers
  8.  Medical Research Laboratories
  9.  Academic Medical Institutes and Universities

On a global scale, ADHD therapeutics market is segmented as follows:

By Drug Type

  1. Stimulants
  2. Amphetamine
  3. Methylphenidate
  4. Dextroamphetamine
  5. Dexmethylphenidate
  6. Lisdexamfetamine
  7. Dimesylate


  1. Atomoxetine
  2. Bupropion
  3. Guanfacine
  4. Clonidine

By Age Group

  1. Pediatric and Adolescent
  2. Adults

By Distribution Channel

  1. Specialty Clinics
  2. Hospital Pharmacies
  3. Retail Pharmacies
  4. e-Commerce

By Region

  1. North America
  2. Latin America
  3. Europe
  4. Asia Pacific
  5. Middle East & Africa

The study shows that among regions, the European market is estimated to account for the maximum revenue share of 62.0% of the global ready-to-use therapeutic food by the end of 2016. It is forecasted to be valued at at US$ 171.0 Mn by 2016 end and is expected to increase to US$ 355.7 Mn by 2024 end, registering a CAGR of 9.6% during the forecast period.

Related Articles

© 2020 ITECHPOST, All rights reserved. Do not reproduce without permission.
Real Time Analytics